IP Group

IP Group stands as a pioneering force in science-based investment, dedicated to accelerating scientific breakthroughs that shape a better future. Recognized as the most active early-stage science investor in the United Kingdom, the firm strategically identifies, develops, and nurtures groundbreaking businesses across deeptech, life sciences, and cleantech sectors, with the latter spearheaded by their specialized division, Kiko Ventures. Their comprehensive approach combines financial backing with strategic guidance, enabling transformative ideas to evolve into market-ready innovations with global impact potential.

The investment portfolio of IP Group showcases their exceptional ability to identify revolutionary technologies with significant commercial promise. Their impressive track record includes backing industry-transforming companies such as Oxford Nanopore Technologies plc, whose DNA/RNA sequencing technology has revolutionized genomic analysis; First Light Fusion, pioneering innovative approaches to clean energy generation; Hysata, developing breakthrough hydrogen electrolyzer technology; and Oxbotica, a leader in autonomous vehicle software. These investments demonstrate IP Group's commitment to supporting ventures that address critical global challenges through scientific innovation.

Beyond direct investments, IP Group operates Parkwalk, which has established itself as the UK's largest growth EIS fund manager, specifically focused on commercializing academic research. This strategic arm allows IP Group to tap into the rich innovation ecosystems of prestigious universities and research institutions, creating a pipeline of opportunities emerging from centers of academic excellence. Their specialist investment team combines deep sector expertise with international perspective, enabling them to evaluate complex scientific propositions and provide valuable guidance to portfolio companies navigating the challenging journey from laboratory to marketplace.

As a publicly traded entity on the London Stock Exchange's Main Market under the ticker IPO, IP Group maintains transparency and accountability to shareholders while pursuing its mission of science-based value creation. The firm typically engages with companies at their earliest stages, often pre-revenue, and continues supporting them through critical growth phases with follow-on investments and strategic guidance. This long-term partnership approach has positioned IP Group as a crucial catalyst in the commercialization of scientific innovation, bridging the gap between academic discovery and commercial application while generating returns for investors who share their vision of science-driven progress.